Alvotech and Lotus Pharmaceutical announce a licensing agreement for two biosimilar candidates in the U.S. and select Asian markets.
Quiver AI Summary
Alvotech, a biotechnology company specializing in biosimilar medicines, has announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical to develop and market two of its biosimilar candidates in the U.S. and select Asian markets. The candidates include AVT34, a proposed biosimilar to Imfinzi® for cancer treatment, and AVT87, a proposed biosimilar to Hemlibra® for patients with hemophilia A. The agreement allows Alvotech to retain commercialization rights in the U.S., while Lotus will have exclusive rights in eight Asian markets. This partnership is valued at up to $150 million and aims to enhance access to high-quality biologics in key markets, reinforcing both companies' growth strategies. Alvotech's CEO emphasized the agreement’s importance for their commercial strategy, while Lotus’s CEO highlighted the expansion of their biosimilar portfolio.
Potential Positives
- Alvotech entered a strategic licensing and commercialization agreement with Lotus Pharmaceutical for two biosimilar candidates, potentially enhancing its market position and revenue streams in the United States and Asia.
- The agreement has a potential value of up to approximately $150 million in upfront and milestone payments, in addition to ongoing revenues from product supply, which could significantly bolster Alvotech's financial outlook.
- For the first time, Alvotech can directly participate in the commercialization of its products in the U.S., allowing it to retain a greater share of the value from its development and manufacturing efforts.
- Lotus Pharmaceutical's established market presence and Alvogen's U.S. commercial platform may accelerate the reach and adoption of Alvotech's biosimilar products, broadening access to high-quality medicines for patients.
Potential Negatives
- Alvotech has entered a semi-exclusive agreement with Lotus, which might limit its control over the commercialization strategy in the United States compared to a fully exclusive arrangement.
- The reliance on Lotus Pharmaceuticals for commercialization in selected Asian markets could expose Alvotech to risks related to regulatory approvals and market access that are beyond its direct control.
- The financial success of the agreement is contingent on various factors, including regulatory approvals and market performance, which introduces uncertainty and potential risk to Alvotech's projected revenues.
FAQ
What is the recent agreement between Alvotech and Lotus Pharmaceutical?
Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for two biosimilar candidates in the U.S. and select Asian markets.
What biosimilar candidates are included in the Alvotech and Lotus agreement?
The agreement includes AVT34, a biosimilar to Imfinzi®, and AVT87, a biosimilar to Hemlibra®.
What markets will Lotus Pharmaceutical operate in for these biosimilars?
Lotus will have exclusive rights to commercialize the products in South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong, and Malaysia.
What is the potential financial value of the agreement for Alvotech?
The agreement could provide Alvotech with up to approximately $150 million in upfront and milestone payments, plus ongoing revenues.
How will Alvotech and Lotus Pharmaceutical collaborate under this agreement?
Alvotech will directly commercialize the products in the U.S. while Lotus will handle commercialization in select Asian markets through Alvogen.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 42 institutional investors add shares of $ALVO stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP added 15,677,093 shares (+inf%) to their portfolio in Q2 2026, for an estimated $57,848,473
- MILLENNIUM MANAGEMENT LLC added 2,141,048 shares (+100.9%) to their portfolio in Q2 2026, for an estimated $7,900,467
- CITADEL ADVISORS LLC added 1,728,002 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,376,327
- BRACEBRIDGE CAPITAL, LLC added 1,333,333 shares (+49.3%) to their portfolio in Q2 2026, for an estimated $4,919,998
- POINTSTATE CAPITAL LP removed 1,049,039 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $3,598,203
- ROYCE & ASSOCIATES LP added 558,144 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,059,551
- JPMORGAN CHASE & CO added 529,689 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,954,552
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ALVO Price Targets
Multiple analysts have issued price targets for $ALVO recently. We have seen 2 analysts offer price targets for $ALVO in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $4.0 on 03/24/2026
- Ashwani Verma from UBS set a target price of $6.0 on 03/24/2026
Full Release
REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to Hemlibra® (emicizumab).
Imfinzi® is an oncology biologic used in the treatment of multiple cancers, which generated global sales of approximately $6.1 billion in 2025¹. Hemlibra® is a biologic for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A that generated global sales of approximately CHF4.8 billion (approximately $5.8 billion) in 2025².
Under a semi-exclusive agreement in the United States, Alvotech retains the right to commercialize both products directly alongside Lotus, while Lotus will commercialize the products through Alvogen, its U.S.-based wholly owned subsidiary. Alvotech will retain responsibility for product development, and for obtaining and maintaining marketing authorizations in the United States, and will serve as the exclusive supplier of the products for all markets.
In Asia, Lotus will have exclusive commercialization rights in eight selected markets: South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia. Lotus will be responsible for local regulatory submissions and commercialization in these markets.
The agreement has a potential value to Alvotech of up to approximately $150 million in upfront and milestone payments, in addition to ongoing revenues from the supply of commercial product.
“This agreement represents an important evolution of Alvotech’s commercial strategy,” said Lisa Graver, Chief Executive Officer of Alvotech . “For the first time, we will have the opportunity to participate directly in the future commercialization of our products in the United States, allowing us to retain a greater share of the value we create through our development and manufacturing platform. At the same time, our partnership with Lotus extends the potential reach of these two important pipeline assets across key Asian markets. We look forward to working together to bring these medicines to patients and broaden access to high-quality biologics.”
“We are pleased to partner with Alvotech on two important biosimilar candidates that meaningfully advance Lotus’ global growth strategy,” said Petar Vazharov, Chief Executive Officer of Lotus . “By combining Alvotech’s integrated biosimilar development and manufacturing capabilities with Alvogen’s established U.S. commercial platform and Lotus’s deep market presence across Asia, we are building a strong foundation for the future commercialization of AVT34 and AVT87 across key global markets. These candidates expand the scale and reach of our biosimilar portfolio in oncology and rare diseases, and reinforces our commitment to broadening access to high-quality medicines.”
Imfinzi® and Hemlibra® are registered trademarks and the property of their respective owners.
| 1) |
AstraZeneca PLC. (2026). Annual report on Form 20-F for the fiscal year ended December 31, 2025. U.S. Securities and Exchange Commission.
https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm |
| 2) |
Roche, Finance Report 2025, F. Hoffmann-La Roche Ltd,
https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf |
Contacts
Media contacts –
[email protected]
Benedikt Stefansson
Sarah MacLeod
Investor Relations contacts
–
[email protected]
Dr. Balaji V Prasad
Benedikt Stefansson
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our website or follow us on social media on LinkedIn , Facebook , Instagram , and YouTube .
Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.
